SCHEMBL4295044

SCHEMBL4295044

CCOC(=O)C(=O)c1csc(C(=O)OC(C)(C)C)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.43
NPC1 O15118 5/20 0.43
MAPT P10636 4/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ABCB1 P08183 1/20 0.42
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
GAA P10253 3/20 0.38
PLA2G4A P47712 2/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HPGDS O60760 1/20 0.37
HSP90AA1 P07900 1/20 0.36
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14207145 0.85 RAB9A (0.52) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL9529235 0.78 CYP1A2 (0.51) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL13451814 0.76 MAPT (0.47) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL424300 0.75 MAPT (0.46) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL11004517 0.75 MAPT (0.46) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL9454202 0.75 RAB9A (0.66) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL18990185 0.74 CYP1A2 (0.47) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL353584 0.74 ALDH1A1 (0.69) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL10465943 0.74 MAPT (0.45) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL17716411 0.74 HPGDS (0.47) RAB9ANPC1MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 EP disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
CN-101421265-A Thiazole compounds as protein kinase b (pkb) inhibitors AMGEN INC (US) 2009-04-29 CN disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
EP-1981884-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS Amgen, Inc (US) 2008-10-22 EP disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 WO disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 RAB9A 3483/4885NPC1 637/4885MAPT 2665/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 RAB9A 3573/4885NPC1 882/4885MAPT 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.